U.S. Appeals Court Blocks Trump Era 340B Drug Discount Pilot Program

The court's decision pauses the rollout of a controversial pilot that aimed to reform drug pricing for hospitals under the 340B program. This legal development underscores persistent challenges in federal drug rebate policies.

TCB TeamJan 8, 20263 min

Background

The 340B program provides discounted drug prices to certain hospitals and health providers.
The Trump administration's pilot sought to alter how rebates were handled under this program.

Court Ruling

A U.S. appeals court panel ruled against allowing the pilot program to proceed for now.
This decision temporarily prevents changes to the existing drug discount framework.

Significance

The ruling highlights the complexity and regulatory scrutiny surrounding federal drug pricing initiatives, particularly ones that impact hospital funding and pharmaceutical rebates.

Source

Trump administration 340B pilot program is thwarted, for now, by a U.S. appeals court

The Catalyst Brief

Independent biotech intelligence, every week.

Get curated biotech intelligence across AI, industry, innovation, investment, medtech, and policy delivered to your inbox.

Keep reading

UniQure Files AMT-130 For FDA And U.K. Review, Reopening A Huntington’s Gene Therapy Path After FDA Reversal

Sep 2, 2026

U.S. Appeals Court Blocks Trump Era 340B Drug Discount Pilot Program

Background

Court Ruling

Significance

Source

Keep reading

UniQure Files AMT-130 For FDA And U.K. Review, Reopening A Huntington’s Gene Therapy Path After FDA Reversal

SEC And FDA Sign Three-Year Information-Sharing Pact, Tightening Biopharma Insider Trading Scrutiny

Amgen Loses New U.K. Tavneos Starts, As FDA Hearing Fight Continues

Juul Gets FDA Clearance For Juul2 With Optional Age Verification, Reopening Its U.S. Device Pipeline